The U.S. Food and Drug Administration (FDA) granted priority review to an application from Axsome Therapeutics seeking approval of its oral therapy AXS-05 to treat agitation related to Alzheimer’s ...

The European Commission has approved Eli Lilly‘s monthly infusion therapy Kisunla (donanemab) for adults with early symptomatic Alzheimer’s disease. The treatment targets sticky protein clumps, or ...

An experimental oral therapy called blarcamesine appears to slow the progression of Alzheimer’s disease, reducing the rate of cognitive decline and preserving daily function over the long term, ...

The U.S. Food and Drug Administration (FDA) has approved a more gradual titration dosing schedule for Kisunla (donanemab) for people with early symptomatic Alzheimer’s disease based on evidence that ...

A new patient advocacy organization, the ApoE4 Alzheimer’s Alliance, has launched in the U.S., with a goal of helping advance both supportive policies and the development of treatments for people with ...

Axsome Therapeutics plans this year to ask the U.S. Food and Drug Administration (FDA) to approve its oral therapy AXS-05 as a treatment for agitation related to Alzheimer’s disease. The company ...

After completing a third review of interim safety data, an independent safety monitoring board has recommended the continuation — without modifications — of two ongoing Phase 3 clinical trials testing ...

Nearly one year of treatment with blarcamesine (Anavex 2-73), a once-daily oral small molecule being developed by Anavex Life Sciences, slowed cognitive and functional decline in people with early ...

The use of Montelukast oral film, an experimental therapy being repurposed by Intelgenx to treat mild to moderate Alzheimer’s disease, led to significant improvements in patients’ cognition versus a ...

Foralumab, an investigational nasal spray being developed by Tiziana Life Sciences, has been cleared by the U.S. Food and Drug Administration (FDA) for expanded use to treat moderate Alzheimer’s ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to Elecsys Phospho-Tau 217 (pTau217), a blood-based biomarker test that can help distinguish Alzheimer’s disease ...

The U.S. Food and Drug Administration (FDA) has lifted a clinical hold on a Phase 2 trial testing INmune Bio’s investigational treatment XPro1595 in people with Alzheimer’s disease. Regulators issued ...